Compare Opendoor Technologies Inc (OPEN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Opendoor Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Opendoor Technologies Inc trades at $3.01 (market cap $2.96B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Opendoor Technologies Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| OPEN | RXRX | |
|---|---|---|
Market Cap | $2.96B | $1.86B |
Sector | Real Estate | Health |
52-Week High | $10.52 | $6.79 |
52-Week Low | $3.00 | $2.84 |
Enterprise Value | $4.03B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Opendoor Technologies (OPEN) trades at $3.07, down 2.54% on the day, near its 52-week low. The stock exhibits a bearish technical trend with negative moving averages, while fundamentals show declining revenue to $4.37 billion in 2025 and a net loss of $1.30 billion. Recent news highlights the launch of Opendoor Home Loans and a $158 million share buyback, but the company faces persistent profitability challenges amid a weak housing market.
The outlook remains cautious with high execution risks and negative margins, though analyst consensus suggests a moderate buy rating with a $3.58 price target. Key risks include housing market sensitivity and capital intensity, but cost-cutting and volume growth offer potential upside if the turnaround gains traction.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
